Recursion Pharmaceuticals (RXRX) shares recently closed at US$3.98, with the stock showing a negative return over the past month and past 3 months, which may prompt investors to reassess its current ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...